WASHINGTON, WEDNESDAY – Three pharmaceutical manufacturers, the United States Government, and nonprofit research institutions work together to test five new breast cancer drug. Cooperation which made the five drug to be marketed as soon as it was announced in Washington, Wednesday (17/3/2010).
Research topic Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis (I-SPY2) was tested DNA analysis approach to determine the best drug for each individual patient.
I-SPY2 also tested DNA analysis approach to identify the type of action and what the treatment is not suitable for each individual patient. Thus, every action and treatment is not suitable for patients can be stopped.
Research that will last for five years to get the budget 26 million U.S. dollars. Third pharmaceutical manufacturers involved in the research, Abbott Laboratories, Amgen, and Pfizer agreed to share information, the effectiveness of DNA analysis approach in estimating the impact of their production of drugs to the U.S. Biomarkers Consortium. Research information will also be distributed to the National Agency for Drug and Food United States (FDA) and the U.S. National Institutes of Health (National Institutes of Health).
“I think this kind of research could be a model in future research,” said Deputy Director of the U.S. National Cancer Institute Anna Barker when contacted Reuters.
“Research I-SPY 2 will be the first step to create individualized treatment for each cancer patient,” says breast cancer surgeon University of California San Francisco, Dr. Laura Esserman. Esserman also will be testing clinic leader of the study.
Drugs used in cancer research is ABT-888 or the production veliparib Abbott Laboratories. The drug that works by blocking cellular repair enzymes needed by cancer cells.
The second drug is AMG 655 (conatumumab) production Amgen, which is a kind of barrier APO / TRAIL causes cancer cells to destroy themselves.
The third drug being tested is AMG 386, also developed by Amgen. The drug works by stopping the ability of tumor blood flow in the tumor cells.
Two final drug is Pfizer’s production, CP-751, 871 (figitumumab) and HKI-272 (neratinib). CP-751, 871 that attacks the nerve endings of insulin growth factor (IGFR), whereas HKI-272 works by destroying a number of the recipient nerve stimulation on cancer cells. (row)
Source: Symptom Of Breast Cancer